Loading patent…
AssigneesInserm (Institut National De La Santé Et De La Recherch MéDicale), Université Paris Cité, Assistance Publique-Hopitaux de Paris
InventorsEric TARTOUR, Stephane OUDARD, Ikuan SAM, Nadine BEN HAMOUDA
Estimating the term…
Inventors have shown that CD70 and CD27 are highly expressed in ccRCC and correlates with poor survival. Multiplex IF demonstrated that CD27+T cells interact with CD70+ tumor cells in tumor microenvironment (TME). CD27+T cells are more apoptotic than CD27−T cells in ccRCC. Elevated levels of plasma sCD27 is observed in ccRCC patients and correlates with CD27−CD70 interaction in situ. Their study demonstrates that CD27−CD70 interaction contributes to the release of sCD27 in peripheral blood in ccRCC, indicating that sCD27 is a potential biomarker. The apoptosis of CD27+T cells suggests the deleterious effect of CD27−CD70 interaction in T cell response. Therefore, CD27/CD70 is a promising therapeutic target in ccRCC. Accordingly, the invention relates to a method for determining the interaction between CD27 and CD70 by determining the level of soluble CD27 (sCD27) in a biological sample and to method of targeting CD27/CD70 interaction to treat a cancer or metastatic cancer.
(canceled)
(canceled)
A method for predicting whether a subject suffers from or is susceptible to suffer from a cancer and/or metastatic cancer expressing CD70 and treating the subject, comprising:
A method for treating cancer and/or metastatic cancer in a subject in need thereof comprising administering to said subject a therapeutically effective amount of an inhibitor of interaction of CD27/CD70.
A method of preventing and/or treating cancer and/or metastatic cancer in a subject in need thereof, comprising, administering to the subject a therapeutically effective amount of an inhibitor of interaction of CD27/CD70 and a classical cancer treatment.
Dependencies are inferred from the claim text.